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Objective: The Inventory to Measure and Assess imaGe disturbance – Head and Neck
(IMAGE-HN) is a validated patient-reported outcome measure of head and neck cancerrelated body image-related distress (BID). However, the IMAGE-HN score corresponding
to clinically relevant BID is unknown. The study objective is to determine the IMAGE-HN
cutoff score that identifies head and neck cancer patients with clinically relevant BID.
Methods: We conducted a cross-sectional study at six academic medical centers.
Individuals ≥18 years old with a history of head and neck cancer treated with definitive
intent were included. The primary outcome measure was the IMAGE-HN. A Receiver
Operating Characteristic curve analysis was performed to identify the IMAGE-HN score
that maximized sensitivity and specificity relative to a Body Image Scale score of ≥10
(which indicates clinically relevant BID in a general oncology population). To confirm the
validity of the IMAGE-HN cutoff score, we compared the severity of depressive [Patient
Health Questionnaire-9 (PHQ-9)] and anxiety symptoms [Generalized Anxiety Disorder-7
(GAD-7)], and quality of life [University of Washington-QOL (UW-QOL)] in patients with
IMAGE-HN scores above and below the cutoff.
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Results: Of the 250 patients, 70.4% were male and the mean age was 62.3 years. An
IMAGE-HN score of ≥22 was the optimal cutoff score relative to a Body Image Scale
score of ≥10 and represents a clinically relevant level of head and neck cancer-related
BID. Relative to those with an IMAGE-HN score of <22, patients with IMAGE-HN scores
of ≥22 had a clinically meaningful increase in symptoms of depression (mean PHQ-9
score difference = 5.8) and anxiety (mean GAD-7 score difference = 4.1) as well as worse
physical (mean UW-QOL score difference = 18.9) and social-emotional QOL (mean UWQOL score difference = 21.5). Using an IMAGE-HN cutoff score ≥22, 28% of patients
had clinically relevant BID.
Conclusion: An IMAGE-HN score of ≥22 identifies patients with clinically relevant
head and neck cancer-related BID. This score may be used to detect patients who
could benefit from strategies to manage their distress, select patients for studies
evaluating interventions to manage head and neck cancer-related BID, and improve
our understanding of the underlying epidemiology of the disorder.
Keywords: body image distress, disfigurement, head and neck cancer, depression, anxiety, quality of life, patientreported outcome measure (PROM), survivorship

INTRODUCTION

(Graboyes et al., 2020a). Although IMAGE-HN underwent
rigorous validation in a multi-institutional cohort, the IMAGEHN score that corresponds to clinically relevant BID remains
unknown. As a result, clinicians and researchers are limited
in their ability to identify patients with HNC-related BID,
preventing appropriate referrals for management of this
devastating disorder and enrollment into clinical trials to test
the efficacy of novel interventions. Therefore, the objective of
this study is to determine the IMAGE-HN score that identifies
clinically relevant BID in patients with HNC.

There are nearly 500,000 head and neck cancer (HNC) survivors
in the United States (US) and this population is growing
exponentially (Tota et al., 2019; Howlader et al., 2020). Because
HNC arises in cosmetically and functionally critical areas, such as
the tongue, jaw, throat, and face, patients with HNC experience
substantial life-altering morbidity related to disfigurement,
difficulty swallowing, impaired smiling, and speaking challenges.
As a result, 75% of patients with HNC express body image
concerns (Fingeret et al., 2012), and it is estimated that up to 20%
meet criteria for body image-related distress (BID) (Melissant
et al., 2021a), a disorder characterized by a distressing selfperceived change in appearance and function (Fingeret et al.,
2012; Rhoten, 2016; Teo et al., 2016; Ellis et al., 2019b). BID
is associated with devastating psychosocial morbidity, such as
social isolation, stigmatization, depression, and decreased quality
of life (QOL) (Fingeret et al., 2012, 2015; Rhoten et al., 2013).
BID, in addition to a number of other factors, contributes to
HNC survivors dying from suicide at 2 times the rate of other
cancer types and 4 times that of the US general population
(Osazuwa-Peters et al., 2018, 2021).
Due to its subjective nature and poor correlation with
objective measures of disfigurement (Manier et al., 2018;
Graboyes et al., 2020a), BID is best measured using patientreported outcome measures (PROMs). Unfortunately, the
PROMs that have been used to assess BID in patients with
HNC have been limited by concerns about construct validity
and psychometric performance (Ellis et al., 2019a). The
Inventory to Measure and Assess imaGe disturbance – Head
and Neck (IMAGE-HN) was created to fill this gap (Graboyes,
2021). IMAGE-HN is a psychometrically valid 24-item PROM
developed in accordance with the Patient Reported Outcomes
Measurement Information System (PROMIS) guidelines
(PROMIS, 2013) to comprehensively assess HNC-related BID
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MATERIALS AND METHODS
Study Design and Patients
A cross-sectional study was conducted at six academic medical
centers in the US (Medical University of South Carolina,
Washington University School of Medicine, the University of
Pittsburgh School of Medicine, Vanderbilt University Medical
Center, Henry Ford Health System, and the Medical College
of Wisconsin). This study was approved by the institutional
review board at each institution. Individuals ≥18 years old
with a history of HNC (i.e., oral cavity, pharynx, larynx,
nose/paranasal sinuses, major salivary gland, or cutaneous
structures of the head and neck) who had undergone definitive
treatment and were free of known active disease were eligible
for the study. Patients were excluded if they were unable to
read English. Patients were recruited during routine followup or survivorship visits at multidisciplinary head and neck
oncology clinics from November 2020 to August 2021 and
enrolled face-to-face by a study team member following provision
of written informed consent. Following enrollment, patients
completed study assessments using an electronic tablet. Of
284 patients approached for participation, 23 declined and
11 did not provide demographic or oncologic data, leaving a
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sample of 250. Patients were compensated $10 for participation.
This study followed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting
guideline (von Elm et al., 2014).

Quality of Life
The fourth version of the University of Washington-QOL (UWQOL) is an HNC-specific questionnaire with 12 domains (pain,
appearance, activity, recreation, swallowing, chewing, speech,
shoulder, taste, saliva, mood, and anxiety) that assesses QOL
within the past 7 days (Rogers et al., 2002). This tool was chosen as
it is one of the most widely used HNC-specific measures of QOL
(Pateman et al., 2017). Individual domain questions have between
3 and 6 response options scaled evenly from 0 (worst) to 100
(best), according to the hierarchy of response (Rogers et al., 2002).
The global UW-QOL score can be broken into two subscale
scores, physical function (domains chewing, swallowing, speech,
taste, saliva, and appearance) and social-emotional function
(domains anxiety, mood, pain, activity, recreation, and shoulder
function) (Rogers et al., 2010). Established cutoff scores are
not known. A difference of ≥7 points between groups on the
UW-QOL composite score is considered clinically important
(Vartanian et al., 2004).

Outcome Measures
Head and Neck Cancer-Related Body Image-Related
Distress
The primary outcome measure was the IMAGE-HN global
score. The IMAGE-HN is a 24-item PROM that assesses
multiple domains of HNC-related BID including other-oriented
appearance concerns, personal dissatisfaction with appearance,
distress with functional impairments, and social avoidance
and isolation. Global IMAGE-HN scores range from 0 to 84,
with higher scores indicating more severe HNC-related BID
(Graboyes et al., 2020a). The IMAGE-HN instrument and scoring
manual are publicly available (Graboyes, 2021).

Legacy Measure of Body Image-Related Distress

Other Study Variables

The Body Image Scale (BIS) is a 10-item PROM that assesses the
affective, cognitive, and emotional aspects of body image due to
cancer or its treatment over the prior 7 days (Hopwood et al.,
2001). Initially developed for breast cancer patients, the BIS has
been widely used to study BID in patients with HNC although
it has not been specifically validated in this population (Fingeret
et al., 2012; Ellis et al., 2019a). Higher scores indicate greater body
image concerns and a BIS score of ≥10 corresponds to clinically
relevant BID in general oncology patients (Chopra et al., 2020).

Self-reported sociodemographic characteristics include age,
gender, race, ethnicity, marital status, living situation,
education, employment, rurality, and insurance coverage.
Self-reported oncologic characteristics include tumor subsite,
cancer treatment, and type of reconstructive surgery. Time since
completion of treatment was collected in months.

Statistical Analysis
Descriptive statistics (e.g., frequencies and percent for categorical
variables, mean, and standard deviation for continuous variables)
were used to characterize the sample. To determine the IMAGEHN cutoff score that represents clinically meaningful HNCrelated BID, we performed a Receiver Operating Characteristic
(ROC) curve analysis to identify the IMAGE-HN score that
maximized sensitivity and specificity relative to a BIS score
of ≥10 (which indicates clinically relevant BID in a general
oncology population) (Chopra et al., 2020). We did this by
selecting the point on the ROC curve that minimized the
Euclidean distance to the (0,1) point. To examine the clinical
validity of our newly defined IMAGE-HN cutoff score, we
compared the severity of associated symptoms of depression
and anxiety, and QOL (mean PHQ-9, GAD-7, and UW-QOL
scores, respectively) in those with and without HNC-related
BID, using independent samples t-tests. We used Fisher’s Exact
tests to compare these subgroups on the proportions of patients
with moderate depressive symptoms (defined as PHQ-9 score of
≥10) and anxiety symptoms (defined as GAD-7 score of ≥10)
(Spitzer et al., 2006; Hinz et al., 2016). Statistical analyses were
performed using SAS. A two-sided P < 0.05 was considered
statistically significant.

Depression
Depression was measured using the Patient Health
Questionnaire-9 (PHQ-9), a reliable and validated 9-item
measure of depressive symptoms (Kroenke et al., 2001). The
PHQ-9 was selected because of its performance in patients
with HNC (Shunmugasundaram et al., 2020) and because it is
among the measures recommended by the American Cancer
Society (ACS) and American Society of Clinical Oncology
(ASCO) to screen for depressive symptoms (Andersen et al.,
2014; Cohen et al., 2016). Scores range from 0 to 27, with higher
scores reflecting more severe depressive symptoms. Established
cutoff scores of 5, 10, 15, and 20 indicate mild, moderate,
moderately severe, and severe depressive symptoms, respectively.
A difference of ≥3–4 points between groups on the PHQ-9 is
considered clinically important (Kroenke et al., 2020).

Anxiety
The Generalized Anxiety Disorder-7 (GAD-7) is a validated 7item measure of anxiety symptoms. The GAD-7 was chosen
because it is the recommended tool to screen for anxiety
symptoms in patients with cancer by the ACS and ASCO
(Andersen et al., 2014; Cohen et al., 2016). Scores range from 0 to
21, with higher scores indicating more severe anxiety symptoms.
Cutoff scores of 5, 10, and 15 are indicative of mild, moderate,
and severe anxiety symptoms, respectively (Spitzer et al., 2006).
A difference of ≥3 points between groups on the GAD-7 is
considered clinically important (Kroenke et al., 2019).

Frontiers in Psychology | www.frontiersin.org

RESULTS
Sample Characteristics
A total of 250 patients were included in the study. Table 1
demonstrates the demographic and clinical characteristics of

3

December 2021 | Volume 12 | Article 794038

Macias et al.

IMAGE-HN Cutoff Score

TABLE 1 | Participant characteristics.
Variable

Years of age, Mean ± SD

TABLE 1 | (Continued)
N (%)

IMAGE-HN
Mean ± SD

Variable

62.3 ± 11.9

N (%)

IMAGE-HN
Mean ± SD

10.1 ± 15.3

Reconstructive surgery

Sex

None

80 (39.8)

Female

74 (29.6)

20.9 ± 20.9

Other (including local or regional flap)

25 (12.4)

18.3 ± 18.2

Male

176 (70.4)

13.4 ± 13.4

Microvascular free flap

96 (47.8)

21.3 ± 18.6

224 (89.6)

15.0 ± 15.0

No

66 (68.8)

18.7 ± 17.1

African American

20 (8.0)

16.6 ± 16.6

Yes

30 (31.2)

26.7 ± 20.6

Other

6 (2.4)

34.0 ± 25.8

Time since completion of treatment
0–11 months

111 (43.7)

15.9 ± 16.0

2 (0.8)

2.0 ± 2.8

1–5 years

106 (41.7)

15.6 ± 19.0

237 (94.8)

15.0 ± 16.4

>5 years

22 (8.7)

12.3 ± 13.9

11 (4.4)

31.0 ± 26.6

Unknown

15 (5.9)

19.3 ± 16.8

Race
White

Osseous microvascular free flap reconstruction

Ethnicity
Hispanic
Non-hispanic
Prefer not to answer
Marital status

Academic medical center

Married/current partner

174 (69.6)

13.6 ± 15.6

Medical University of South Carolina

63 (25.2)

18.7 ± 20.9

Single

34 (13.6)

22.4 ± 21.0

Washington University School of Medicine

62 (24.8)

15.0 ± 17.0

Separated/divorced/widowed

42 (16.8)

18.5 ± 18.6

University of Pittsburgh School of Medicine

50 (20.0)

13.0 ± 16.1

Vanderbilt Ingram Cancer Center

10 (4.0)

16.2 ± 14.6

Living situation
Spouse

167 (66.8)

13.9 ± 15.7

Medical College of Wisconsin

50 (20.0)

15.5 ± 14.1

Parents/children/friends/other

45 (18.2)

19.9 ± 22.0

Henry Ford Health System

15 (6.0)

13.3 ± 14.6

Self

38 (15.0)

17.8 ± 16.0

Less than high school

11 (4.4)

22.9 ± 24.7

High school graduate

73 (29.2)

17.8 ± 17.9

Some college

68 (27.2)

16.7 ± 17.4

College graduate

56 (22.4)

14.4 ± 17.3

Graduate school

42 (16.8)

9.6 ± 10.9

Employed (either part or full-time or homemaker)

94 (37.6)

15.5 ± 17.7

Not employed (disability or unemployed)

48 (19.2)

26.3 ± 19.3

Retired

108 (43.2)

10.9 ± 13.4

a Includes

radiation and/or chemotherapy.

Educational attainment

the cohort as well as the mean IMAGE-HN scores (and SD)
for each sociodemographic and treatment-related variable. The
mean age (SD) was 62.3 (11.9) years; 94.8% (237/250) were
non-Hispanic white, and 70.4% (176/250) were male. The
most common HNC subsites were oral cavity (35.2%; 88/250),
oropharynx (30.4%; 76/250), and larynx/hypopharynx (14.8%;
37/250). Eighty percent of patients were treated with a surgicalbased paradigm (201/250) and 47.8% (96/201) underwent free
flap reconstruction. The mean (SD) duration since completion
of treatment was 22.5 (26.0) months. Of the study patients,
25.2% (63/250) were from the Medical University of South
Carolina; 24.8% (62/250) from the Washington University School
of Medicine, and 20.0% (50/250) each from the University of
Pittsburgh School of Medicine and Medical College of Wisconsin.

Employment

Rurality
Rural

103 (41.2)

15.8 ± 17.5

Suburban

112 (44.8)

15.0 ± 16.6

Urban

35 (14.0)

17.2 ± 18.2

Insurance
Private

96 (38.4)

14.5 ± 16.6

Medicare

116 (46.4)

14.9 ± 17.3

Medicaid/self-pay/other

38 (15.2)

20.5 ± 17.6

Oral cavity

88 (35.2)

17.6 ± 18.8

Oropharynx

76 (30.4)

10.5 ± 14.4

Larynx/hypopharynx

37 (14.8)

20.5 ± 18.0

Nasal cavity/paranasal sinuses/nasopharynx

13 (5.2)

22.3 ± 11.3

Major salivary gland

12 (4.8)

17.3 ± 13.0

Facial cutaneous malignancy

16 (6.4)

11.7 ± 17.9

Other or unknown

8 (3.2)

14.4 ± 21.9

Tumor location

Clinically Relevant Inventory to Measure
and Assess imaGe Disturbance – Head
and Neck Score
An IMAGE-HN score of ≥22 was the optimal dichotomization
value relative to a BIS score of ≥10 and represents a clinically
relevant level of HNC-related BID (Figure 1). Relative to a
BIS ≥10, an IMAGE-HN cutoff score ≥22 was highly sensitive
at identifying patients with HNC-related BID (area under
curve = 0.96). Overall, 28% of patients with HNC in the cohort
(70/250) had clinically relevant BID as determined by an IMAGEHN score ≥22. An IMAGE-HN score of ≥22 identified 28
additional patients (11% of the study sample) as having clinically

Cancer treatment
Surgery

68 (27.2)

12.5 ± 16.9

Surgery and adjuvant radiation

77 (30.8)

17.9 ± 18.2

Surgery and adjuvant chemoradiation

56 (22.4)

19.4 ± 18.5

Nonsurgical treatmenta

49 (19.6)

12.0 ± 12.7
(Continued)
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FIGURE 1 | Receiver operating characteristic curve for the IMAGE-HN for identifying clinically relevant HNC-related BID. Area under the curve = 0.96. The red dot
represents the IMAGE-HN score that maximized sensitivity and specificity relative to a BIS score of ≥10.

(SD = 20.6) vs. 83.9 (SD = 13.8); mean difference = 21.5;
p < 0.01 for each]. These differences were also clinically and
statistically significant between those with and without HNCrelated BID. When analyzed using established cutoff scores
for moderate depressive symptoms (PHQ ≥ 10) and moderate
anxiety symptoms (GAD ≥ 10), patients with an IMAGE-HN
score of ≥22 were more likely to have moderate or severe
depressive symptoms (30.0% vs. 5.0%) and moderate or severe
anxiety symptoms (24.3% vs. 3.0%; p < 0.001 for each) relative to
patients with an IMAGE-HN score of <22.

relevant BID who would not have been diagnosed with HNCrelated BID using the legacy measure (BIS ≥10) (Figure 2;
patients in the top left quadrant).

Association of Clinically Relevant
Inventory to Measure and Assess imaGe
Disturbance – Head and Neck Scores
With Depression, Anxiety, and Head and
Neck Quality of Life
Because of the strong association of HNC-related BID with
psychological well-being and QOL, we evaluated the association
of clinically relevant IMAGE-HN scores with symptoms of
depression and anxiety and QOL (Table 2). Relative to those with
an IMAGE-HN score of <22, patients with an IMAGE-HN score
of ≥22 were more likely to experience more severe depressive
symptoms [mean PHQ-9 score = 8.3 (SD = 6.2) vs. 2.5 (SD = 3.4);
mean difference = 5.8] and more severe anxiety symptoms [mean
GAD-7 = 6.7 (SD = 6.0) vs. 2.6 (SD = 3.1); mean difference = 4.1].
These differences between those with and without HNC-related
BID are both clinically and statistically significant. Patients
were also more likely to experience worse physical QOL
[mean UW-QOL physical sub-score = 60.1 (SD = 16.8) vs.
79.0 (SD = 16.3); mean difference = 18.9] and worse socialemotional QOL [mean UW-QOL social-emotional score = 62.4

Frontiers in Psychology | www.frontiersin.org

DISCUSSION
Contribution to the Assessment of Head
and Neck Cancer-Related Body
Image-Related Distress
Although BID has profound consequences in terms of
psychosocial well-being and QOL for patients with HNC,
HNC-related BID remains poorly understood in large part
due to limitations in our ability to measure HNC-related BID
and identify patients with this disorder (Rodriguez et al., 2019;
Graboyes et al., 2020a). The BIS has been used frequently to assess
BID in patients with HNC (Ellis et al., 2019a) and a clinically
relevant cutoff score for the BIS was recently determined
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FIGURE 2 | IMAGE-HN vs. BIS scores. Scatterplot showing the distribution of IMAGE-HN and BIS scores for our study sample. Circles represent the IMAGE-HN
and BIS scores of each patient, with a jitter (small amount of random noise) applied to minimize overlap of observations. Any remaining overlapping observations are
indicated by darker shaded circles. Twenty-eight patients (11% of the cohort) have clinically relevant HNC-related BID as measured by IMAGE-HN score ≥22 who
would not be identified using the BIS (BIS < 10; circles in the upper left quadrant). Forty-two patients (17% of the cohort) have clinically relevant HNC-related BID as
measured by IMAGE-HN score ≥22 who would have been identified by the BIS (BIS > 10; circles in the right upper quadrant). One hundred seventy-five patients
(70% of the cohort) do not have clinically relevant HNC-related BID as measured by IMAGE-HN score < 22, who also have BIS < 10 (bottom left quadrant). Five
patients (2% of the cohort) would not be identified as having clinically relevant HNC-related BID as measured by an IMAGE-HN score < 22 who would have been
identified using a BIS score > 10 (bottom right quadrant).
TABLE 2 | Association of clinically relevant IMAGE-HN scores with depression, anxiety, and head and neck quality of life.
Scale

Full sample (n = 250)

IMAGE-HN < 22 (n = 180)

IMAGE-HN ≥ 22 (n = 70)

p-value

Mean

SD

Mean

SD

Mean

SD

IMAGE-HN1 Global (raw sum)

15.6

17.2

6.8

6.5

38.2

15.3

<0.001

PHQ-92

4.1

5.1

2.5

3.4

8.3

6.2

<0.001

GAD-73

3.4

4.6

2.6

3.1

6.7

6.0

<0.01

Physical

73.7

18.5

79.0

16.3

60.1

16.8

<0.001

Social-Emotional

77.9

18.6

83.9

13.8

62.4

20.6

<0.001

UW QOL v44

1 The

Patient Health Questionnaire-9 is a validated measure of depression. Scores range from 0 to 27 with higher scores reflecting more severe depressive symptoms.
The minimal important difference is ≥3 to 4 points.
2 The Generalized Anxiety Disorder-7 is a validated measure of anxiety. Scores range from 0 to 21 with higher scores indicating worse anxiety symptoms. The minimal
important difference is ≥3 points.
3 The fourth version of the University of Washington-QOL is a HNC-specific questionnaire with 12 domains that assesses quality of life within the last 7 days. Domains are
scaled from 0 (worst) to 100 (best) according to the hierarchy of response. The minimal important difference is ≥7 points.

(Rhondali et al., 2015; Chopra et al., 2020). However, the BIS
lacks content validity for HNC-related BID through its (1)
omission of key appearance (e.g., drooling and facial asymmetry)
and functional (e.g., eating in public and speaking challenges)
concerns and (2) inclusion of items not relevant to patients
with HNC (e.g., “Did you find it difficult to look at yourself
naked?”) (Ellis et al., 2019b). Recently, a number of PROMs have

Frontiers in Psychology | www.frontiersin.org

been developed for, and validated among, patients with HNC
including the IMAGE-HN, FACE-Q, and McGill Body Image
Concerns Scale-Head and Neck Cancer (Cracchiolo et al., 2019;
Rodriguez et al., 2019; Graboyes et al., 2020a). The development
and validation of each of these HNC-specific PROMs represents
significant progress. However, the clinical application of these
PROMs to distinguish between HNC patients with and without
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topics to be addressed by head and neck oncology providers
(Cognetti et al., 2020). Prior to this study, clinicians were limited
in their ability to identify those with clinically relevant HNCrelated BID, inhibiting referrals for further management. Despite
the high prevalence of BID in patients with HNC, evidencebased interventions to manage HNC-related BID are lacking
(Ellis et al., 2019a; Richardson et al., 2019). Preliminary data
from a few recent small studies highlight the promise of a
virtually delivered cognitive behavioral intervention (Graboyes
et al., 2020b) or a structured expressive writing activity as novel
treatments for HNC-related BID (Melissant et al., 2021b). Future
research should utilize validated measures of HNC-related BID
(e.g., IMAGE-HN) to test interventions aimed at reducing BID
in patients with HNC. Furthermore, an IMAGE-HN cutoff score
of ≥22 should be utilized as an inclusion criterion for accrual
into clinical trials to test the efficacy of interventions intended to
decrease HNC-related BID.

clinically relevant BID remains uncertain (Macias et al., 2021).
The current study addresses this key measurement gap. In a large,
multi-institutional cohort, we demonstrated that an IMAGE-HN
score of ≥22 represents a clinically relevant threshold and can
distinguish between those with and without HNC-related BID.
There are two important caveats to interpreting the optimal
IMAGE-HN cutoff score. First, there is no gold standard for the
diagnosis of HNC-related BID [e.g., Diagnostic and Statistical
Manual of Mental Disorders (DSM) diagnosis] against which to
compare the diagnostic accuracy of IMAGE-HN. As a result,
the process for determining score thresholds for HNC-related
BID is not straightforward. However, the approach to IMAGEHN development (Ellis et al., 2019b) ensured that we captured
relevant conceptual constructs of HNC-related BID (Rhoten,
2016; Melissant et al., 2021a) as well as the associated social,
functional, and QOL impairments that are critical to DSM-based
diagnoses. Second, our method of determining an IMAGE-HN
cutoff score aimed to maximize the sensitivity and specificity
of IMAGE-HN relative to the legacy measure (BIS). Another
approach would have been to maximize statistical power, or
the IMAGE-HN score that maximizes the effect size between
those with and without HNC-related BID. Our selected method
was optimized to meet the study objective of most accurately
identifying patients with clinically relevant BID.

Future Directions
As part of a comprehensive and patient-oriented approach to
managing HNC-related BID, the IMAGE-HN can be a powerful
tool to help clinicians and patients identify unmet needs.
However, there are several areas that still need to be addressed
to enhance the clinical relevance of IMAGE-HN. First, the
minimal important difference in IMAGE-HN scores over time
and between groups are unknown; these values are necessary to
evaluate the effectiveness of treatment (Kallogjeri et al., 2020).
Second, while a cutoff score for clinically relevant HNC-related
BID is an important benchmark, BID likely exists on a continuum
and score ranges or thresholds defining disease severity are
lacking. Score thresholds can be ascertained using innovative
techniques such as bookmarking (Cook et al., 2019) and
could guide clinicians and researchers to utilize stepped-therapy
approaches that match treatment intensity to severity of BID.
Moreover, factors affecting the clinical implementation of
IMAGE-HN are not known. HNC-related BID may be difficult
to detect in the clinical setting as symptoms overlap with the
adverse effects of cancer-related treatment. In addition, head
and neck oncology providers are not readily trained to identify
psychosocial concerns, and patients with HNC may be hesitant
to express body image-related concerns (Lydiatt et al., 2013).
Lessening the shame and embarrassment associated with HNCrelated BID is vital to providing high-quality, patient-centered
oncology care, which is associated with improved outcomes,
including survival, and is prioritized by organizations involved
in oncology funding, policy making, and regulation (Basch
et al., 2012; Rotenstein et al., 2017). Routine use of IMAGEHN may help normalize the assessment and treatment of body
image concerns in patients with HNC. While the widespread
utilization of the IMAGE-HN in busy oncology practices is
perhaps unrealistic, adequately screening for and addressing
psychosocial concerns in patients with HNC is likely to decrease
the overall burden on healthcare resources in the long term
by prevention of mental health complications. To improve the
clinical implementation of BID screening among patients with
HNC, additional research is necessary. This may include studies

Epidemiology of Head and Neck
Cancer-Related Body Image-Related
Distress
Findings from the current study can be applied to better
characterize the epidemiology of HNC-related BID. A recent
study by Melissant et al. (2021a) estimated that 13–20% of
HNC survivors had clinically relevant BID as measured by
the BIS. The current study using a HNC-specific measure of
BID (IMAGE-HN) shows that (1) 28% of HNC survivors have
clinically relevant HNC-related BID and (2) 11% of HNC
patients with clinically relevant BID would not have been
identified by the BIS. To our knowledge, this is the first study
to estimate the prevalence of HNC-related BID utilizing a
tool created for and validated in patients with HNC. Future
research should utilize the IMAGE-HN and its cutoff score
to refine our understanding of the trajectory of HNC-related
BID throughout HNC survivorship and better characterize the
prevalence of HNC-related BID in relation to demographic,
oncologic, and treatment characteristics (Graboyes et al., 2019;
Macias et al., 2021).

Clinical and Research Implications of an
Inventory to Measure and Assess imaGe
Disturbance – Head and Neck Cutoff
Score
A second implication of our study is that the IMAGE-HN
cutoff score can now be used in clinical practice and research
studies to identify patients with clinically relevant HNC-related
BID who might benefit from interventions to manage their
distress. A recent national survey showed that body and selfimage-related distress was the least likely of all survivorship

Frontiers in Psychology | www.frontiersin.org

7

December 2021 | Volume 12 | Article 794038

Macias et al.

IMAGE-HN Cutoff Score

to identify high-risk groups for targeted screening, leveraging
alternative screening tools for distress that assess body image
and are already routinely used in the clinical oncology setting
(e.g., NCCN Distress Thermometer), or developing a short-form
of IMAGE-HN. Finally, even if patients with HNC-related BID
are identified in the clinical realm through appropriate screening
tools, significant barriers to the delivery and provision of
appropriate psychosocial oncology care remains (Pirl et al., 2020).
Future research is therefore necessary to investigate the most
thoughtful and balanced approach to diagnosing and treating
HNC-related BID within our current healthcare delivery models.

depression and anxiety and worse QOL when compared to
HNC patients without clinically relevant BID. This score may
be used in clinical practice to identify patients with HNCrelated BID who may benefit from interventions to manage their
distress. Researchers may use the IMAGE-HN cutoff score to
improve our understanding of the underlying epidemiology of
the disorder and better stratify patients for accrual into clinical
trials evaluating novel strategies to manage HNC-related BID.

Strengths and Limitations
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